ArticleCurrent issues in molecular biology2026
MDM2 Alters Cellular Iron Homeostasis by Promoting the Degradation of Proteins Involved in Iron Storage and Iron Export.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The intracellular iron levels are tightly controlled by the coordinated action of specialized proteins that regulate iron uptake, storage, and export pathways in response to iron availability. For example, Ferroportin serves as the sole mammalian iron exporter; whereas ferritin acts as the primary intracellular iron storage complex. Although both Ferroportin and ferritin are reported to be primarily degraded through lysosomal pathways, it is possible that these proteins can also be regulated through the proteasomal pathway, which may provide a more rapid mechanism to modulate intracellular iron availability. Here, we identify MDM2 as a previously unrecognized regulator of cellular iron homeostasis. We found that MDM2 is required to maintain intracellular labile iron. Mechanistically, we found that MDM2 interacts with and promotes the degradation of both Ferroportin and ferritin heavy chain. Consequently, MDM2 exerts a critical role in modulating cellular iron retention by simultaneously suppressing iron storage and iron export pathways. These findings expand the biological functions of MDM2 beyond its established role as a p53 E3 ubiquitin ligase, revealing a previously unappreciated link between MDM2 signaling and iron metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.